How to engage

Four entry points.

Pharma teams arrive in one of four states. We answer each with a different motion.

The platform is one pillar of four. The bridge between consulting, agency, platform, and research is how OVYN captures the full value stack. And how each conversation finds its own way in.

The pillars  ·  four motions
01

Consulting

“We don't know what to do.”

Strategic direction on where pharma marketing is going, where the regulatory pressure points are, and how brands need to be prepared. AI, MLR posture, channel mix, team structure.

The world in pharma is changing. Radioligand therapy, GLP-1 expansion, immuno-oncology, the FDA reclassifications, the agency consolidation. We are the people who watch the gaps and call them out before they cost you the year.

  • . Quarterly strategy reviews
  • . Vertical-specific position papers
  • . Org-restructure recommendations
  • . AI / MLR posture audits
  • . Pre-launch competitive teardown
Retainer or project · premium register
02

Agency

“We don't have bodies.”

White-label execution. Overflow agency capacity, MLR-coordinated production, project management, Veeva/Ziflow integration. Your team, scaled.

Independent agencies and brand teams hit capacity. They have the brief, they have the brand. They just don't have the runway. We come in white-label, run under your name, get the work shipped. Optionally with the platform on top.

  • . White-label production retainers
  • . Project management embed
  • . MLR-coordinated execution
  • . Social activation runs
  • . Integrated regulated launches
Monthly retainer · 10–30K/mo tiers
03

Platform

“We're ready for the platform.”

Brand-as-model content infrastructure. We don't configure a general model with brand rules. We encode each brand as its own model. Identity-first prompt, brand corpus retrieval at inference, dual-rail audit (compliance + brand-fit), per-brand adapter at scale.

When a brand is ready to operate at velocity inside MLR, OVYN is the substrate. Three shells live today across oncology, rare disease, and compounding wholesale. Same architecture per brand, materially different brand worlds. The architecture is the moat: a competitor can copy a prompt template overnight, but they can't replicate a brand encoded into its own model.

  • . Brand essence anchor · identity precedes constraints
  • . Brand corpus retrieval · model anchors on actual shipped content
  • . Three-axis check · compliance rules · model self-check · brand-fit identity scoring
  • . Atmosphere-gated image generation · 5-axis vision scorer
  • . Audit drawer + provenance on every output
$10K/brand · $130–150K for 5-brand commitment · $250K enterprise unlimited
04

Research

“We need to know what's coming.”

Standing market intelligence. Eight live channel adapters (SERP, ClinicalTrials.gov, FAERS, Orange Book, OPDP enforcement, Open Payments, drug-shortage, AI-answer) sweep weekly. Signals stake-scored against the brand essence, composed into a one-paragraph strategic brief plus 3-5 recommended next moves, emailed to subscribers Monday morning. Approved signals auto-promote into the brand corpus.

Not a one-time audit. A standing signal. Eight regulated-pharma source connectors run on a Vercel cron every Monday 11:00 UTC. Each brand gets a brief in the inbox of every subscribed recipient. The signals worth keeping feed the brand canon so generations stay calibrated to where the market actually is. Live as of this week.

  • . Eight channel adapters · SERP · ClinicalTrials.gov · FAERS · Orange Book · OPDP · Open Payments · drug-shortage · AI-answer
  • . Weekly cron sweep · Monday 11:00 UTC
  • . Stake-scored against brand essence
  • . Synthesized weekly brief · paragraph + 3-5 recommended moves
  • . Email delivery to subscriber list · per-brand recipient management
  • . Approved signals → brand corpus (closes the loop)
Starter $3K/mo · Growth $8K/mo · Enterprise $20K+/mo
02 + 03  ·  the bridge

The bridge

Agency + Platform is the move competitors can't make. You get the white-label production, the team capacity, and the IP underneath. Every output runs against the brand brain, scored, audited, and shipped. Premium tier; the only motion that captures the full value stack.

The architecture  ·  brand-as-model

We don’t configure a general model. We encode each brand into its own model.

Most AI marketing tools take a general-purpose model and configure it with brand rules. The brand has to interpret abstract instructions. The output drifts. OVYN inverts the pattern: we encode each brand as four artifacts — essence, corpus, identity classifier, adapter weights — sequenced so each new tenant gets stronger every quarter. Three layers live today, one is the year-1 moat.

A1

Essence anchor

Identity precedes constraints. Before any rule or example, the model reads who the brand IS. Thesis, story, truths, anti-positioning, tells. Closes the gap where rule-compliant variants still read as generic.

Live across all brands.
A2

Brand corpus + retrieval

Beyond 4–9 curated examples, brands ingest 50–500+ pieces of past shipped content. The engine retrieves up to 12 relevant pieces per generation as anchoring material. The model patterns against real brand writing, not abstract rules.

Live across all brands.
A3

Brand-fit identity scoring

Independent axis from compliance. Each variant scored 0–100 against essence + corpus by a few-shot identity judge. Below 60 = off-brand even if compliance-clean. Surfaces in the audit drawer alongside rule-rail provenance.

Live across all brands.
A4

Per-brand text adapter

Every approved execution auto-promotes into the brand's precedent library. At inference time, the top-K precedents are retrieved and injected as match-this-voice anchors. The adapter sharpens with every approval, in real time, with every example fully citable in the audit drawer. The work competitors structurally cannot replicate without your content + your permission.

Year-1 moat work.
Where we lean in  ·  categories

We work pharma broadly. Where we go deep is where the briefs are concentrated and where the regulatory map is moving:

Oncology
37% of open pharma briefs. Biggest pie. Lumen Oncology live as the showcase shell.
Rare disease
Second largest category. Specialized voice rules, MLR-conservative, caregiver + HCP audience structure.
Immunology / immunotherapy
Cross-cuts with oncology. Multi-mechanism explanations, biomarker-anchored content, slow-burn launches.
Radioligand therapy
Emerging modality. Treatment-center operationalization, referring-MD education, payer-pathway content.
Small molecules
Established surface, sophisticated MLR. Where the agency white-label tier earns its keep.

Which state are you in?

zein@ovyn.co  →